Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use-Results Survey of OPDIVO in Unresectable Advanced or Recurrent Malignant Epithelial Tumors (Non-squamous)
jRCT2041240115Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in Epithelial neoplasm, sponsored by Ono Pharmaceutical. Primary endpoint: Comprehensive improvement (best antitumor efficacy by RECIST). Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
Epithelial neoplasm
Beyond the preview
Go deeper on jRCT2041240115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240115.